Skip to content

Real-world study on Tongxinluo's treatment of acute myocardial infarction

A multicenter and prospective cohort study of Tongxinluo in the treatment of acute ST-segment elevation myocardial infarction

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2100005609
Enrollment
Unknown
Registered
2021-12-06
Start date
2021-12-06
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Group 2:Basic Western Medicine Treatment
Group 1:Basic Western Medicine Treatment + Tongxinluo

Sponsors

Hebei Yiling Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: (1) Over 18 years old; (2) The onset of infarct chest pain is within 24 hours; (3) ST-segment elevation in more than 2 adjacent leads of ECG >=0.2mV, or new left bundle branch block; (4) Volunteer to participate in this research and have signed an informed consent form;

Exclusion criteria

Exclusion criteria: (1) Because STEMI is already in critical condition; (2) Patients who have undergone cardiopulmonary resuscitation for a long time (more than 20 minutes); (3) Suspected aortic dissection or acute pulmonary embolism; (4) Patients with clear mechanical complications (including perforation of the ventricular septum, or rupture of the papillary tendon bundle, or the free wall of the left ventricle is being or has been ruptured); (5) Severe cardiogenic shock and no response to blood pressure drugs; (6) Patients with uncontrolled acute left heart failure and pulmonary edema; (7) Patients with malignant arrhythmias that are difficult to control with drugs; (8) Patients who have had a history of hemorrhage in the cerebrovascular, gastrointestinal tract, respiratory tract, urinary tract or other organs in the past month; (9) Patients who still have active bleeding in any part (including menstrual period); (10) Patients with known bleeding constitution, or severe hemostatic and coagulation dysfunction; (11) Patients who are taking therapeutic doses of anticoagulants (such as warfarin or new anticoagulants); (12) Severe chronic obstructive pulmonary disease (COPD) or respiratory failure; (13) Patients with neuropsychiatric diseases; (14) Patients with malignant tumors; (15) Patients who are allergic to the ingredients in this study; (16) Pregnant or lactating women; (17) Patients who are participating in other clinical studies; (18) Patients with other diseases that are not suitable for participating in clinical research.

Design outcomes

Primary

MeasureTime frame
Major adverse cardiovascular and cerebrovascular events (cardiovascular death, resuscitation, emergency coronary revascularization, stroke) rate;

Secondary

MeasureTime frame
All-cause mortality;Compound endpoint event rate(MACCE, re-admission for heart failure, severe bleeding (BARC III and V));

Countries

China

Contacts

Public ContactJia Zhenhua

Hebei Yiling Hospital

ylyylcky@163.com+86 03118385881

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026